Multi-organoid culture device and metabolic disease model preparation method using same

The multi-organoid culture device with convection-based mass transfer and semipermeable membranes addresses the limitations of single-tissue organoids by efficiently replicating liver-pancreas axis diseases, achieving rapid glucose homeostasis and stable long-term culture for drug screening and disease analysis.

WO2026240445A1PCT designated stage Publication Date: 2026-11-19IND ACADEMIC COOPERATION FOUND UNIV OF INCHEON +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/006078
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-15
Filing Date
2026-05-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing single-tissue organoids struggle with passive material exchange, leading to slow glucose transfer and reaction rates, limiting the replication of complex metabolic pathways and physiological interactions, particularly in liver-pancreas axis diseases like MASLD and T2DM, and long-term culture results in physiological imbalances.

Method used

A multi-organoid culture device with a convection-based mass transfer system using semipermeable membranes to separate and connect liver and pancreas organoids, mimicking circulatory flow, enabling efficient metabolite exchange and maintaining tissue-specific functions.

Benefits of technology

The device effectively replicates the liver-pancreas axis pathology, allowing rapid glucose homeostasis and stable long-term culture, preserving tissue viability and functionality, and facilitating drug screening and disease mechanism analysis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026006078_19112026_PF_FP_ABST
    Figure KR2026006078_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a multi-organoid culture device, a multi-organoid test method using the same, a metabolic disease model preparation method, and a drug screening method. A multi-organoid culture device according to the present invention comprises: a body having formed therein a first chamber in which a first organoid can be cultured and a second chamber in which a second organoid can be cultured, and including a first flow path to which one side of the first chamber and one side of the second chamber are connected; a second flow path fluidly connected to both ends of the first flow path; and a pressing means for generating fluid flow in the first flow path.
Need to check novelty before this filing date? Find Prior Art

Description

Multi-organoid culture device and method for manufacturing a metabolic disease model using the same

[0001] The present invention relates to a multi-organoid culture apparatus, a multi-organoid testing method using the same, a method for manufacturing a metabolic disease model, and a drug screening method.

[0002]

[0003] Obesity is a condition characterized by the excessive accumulation of fat in the body due to an imbalance between energy intake and expenditure, and it is a major risk factor for various metabolic diseases. Obesity, which induces insulin resistance, is closely linked to Type 2 diabetes (T2DM) and can also lead to metabolic dysfunction-associated steatotic liver disease (MASLD), characterized by the abnormal accumulation of fat in the liver. MASLD is a concept that emphasizes the association with metabolic diseases beyond simple fatty liver; it can occur even in individuals with normal weight or without diabetes, and in such cases, insulin resistance is frequently present. MASLD is reported to be not only an independent risk factor for T2DM but also increases the prevalence of coronary artery disease and cerebrovascular disease, as well as the risk of cardiovascular mortality. Recently, attention has been focused on the pathological associations in which metabolic diseases such as diabetes can cause MASLD, and conversely, MASLD can induce the development of diabetes.

[0004] At the center of these interactions lies the liver-pancreas axis, which plays a key role in maintaining metabolic homeostasis, particularly in blood glucose regulation. The liver regulates blood glucose levels by storing or breaking down glucose into glycogen, while the pancreas regulates the liver's metabolic activity by secreting insulin and glucagon. MASLD is a disease characterized by hepatic fat accumulation accompanied by metabolic abnormalities, and it is known to be present in approximately 60% of patients with T2DM. Hepatic fat accumulation induces insulin resistance, leading to increased hepatic glucose production; this, in turn, results in a decline in pancreatic β-cell function, which adversely affects blood glucose control. Consequently, MASLD and T2DM are pathophysiologically linked, creating a vicious cycle, and this relationship is known to stem from dysfunction of the liver-pancreas axis.

[0005] Organoids are small organ mimics created by culturing stem cells in three dimensions to possess structures and functions similar to actual organs. Compared to conventional two-dimensional cultures, they preserve gene expression and mutation characteristics better and can maintain the functions and biological characteristics of progenitor cells for extended periods, making them useful in various fields such as disease research, new drug development, and precision medicine. However, most are composed of a single tissue, making it difficult to reflect complex interactions between organs, and there are limitations in implementing metabolic reactions similar to the biological environment due to passive diffusion-based mass transfer.

[0006] To overcome the limitations of existing single-tissue-based organoids, co-cultured organoids are being developed that induce interactions by culturing two or more tissues together. However, current co-culture technology relies on passive material exchange, which results in slow glucose transfer and reaction rates, limiting its ability to replicate glucose homeostasis. Furthermore, during long-term culture, different tissues are exposed to the same culture medium, which can lead to physiological imbalances. These limitations act as obstacles to mimicking complex in vivo metabolic pathways.

[0007] Against this backdrop, the inventors developed an organoid culture device capable of realizing the physiological interaction between the liver and the pancreas by establishing a convection-based mass transfer system that mimics human circulatory flow and independent organoid culture environments separated by a semipermeable membrane. The present invention was completed by confirming that major pathological features related to metabolic diseases were successfully reproduced as a result of reproducing the MASLD-T2DM pathology model using the device.

[0008]

[0009] The object of the present invention is to provide a multi-organoid culture device comprising: a body having a first chamber formed therein for culturing a first organoid and a second chamber for culturing a second organoid, and a first flow path connecting the first chamber and the second chamber to each other on one side; a second flow path fluidically connected to both ends of the first flow path; and a pressurizing means for generating fluid flow within the first flow path.

[0010] Another objective of the present invention is to provide a multi-organoid testing method using the multi-organoid culture device, wherein the multi-organoid culture device further comprises a reservoir having one end fluidically connected to the first fluid path and the other end fluidly connected to the outside of the body, and comprising: a culture step of culturing the first organoid and the second organoid in the first chamber and the second chamber; and a first test step of testing the cultured first organoid and the second organoid.

[0011] Another objective of the present invention is to provide a method for manufacturing a metabolic disease model using the multi-organoid culture device described above.

[0012] Another objective of the present invention is to provide a drug screening method comprising the step of treating a model prepared by the above-described manufacturing method with a candidate substance for the prevention or treatment of metabolic diseases.

[0013]

[0014] To achieve the above objective, the present invention provides a multi-organoid culture device comprising: a body having a first chamber in which a first organoid can be cultured and a second chamber in which a second organoid can be cultured formed internally, and a first flow path in which the first chamber and the second chamber are respectively connected to one side; a second flow path fluidically connected to both ends of the first flow path; and a pressurizing means for generating fluid flow within the first flow path.

[0015] At this time, a first filter that selectively passes a substance between the first chamber and the first flow path may be disposed in the first connection part where the first chamber and the first flow path are connected.

[0016] At this time, a second filter that selectively passes a substance between the second chamber and the first flow path may be disposed in the second connection part where the second chamber and the first flow path are connected.

[0017] At this time, the first chamber and the second chamber may be spaced apart by a predetermined distance within the body.

[0018] The above distance may be 0.5 to 3 mm, preferably 0.8 to 1.2 mm, but is not limited thereto.

[0019] At this time, it may further include a reservoir in which one end is fluidly connected to the first Euro and the other end is fluidly connected to the outside of the body.

[0020] At this time, the body is formed by combining a first plate, a second plate, and a third plate that are stacked in one direction, a first chamber and a second chamber are formed within the first plate, a first connecting part penetrating the second plate and a second connecting part are formed in the second plate, and a first flow path groove having a shape corresponding to a first flow path may be formed in the third plate.

[0021] In this case, the first organoid is a liver organoid, and the second organoid may be a pancreas organoid.

[0022] The above pressurizing means can be operated at a flow rate of 100 to 1000 μL / min, preferably at a flow rate of 200 to 800 μL / min, and most preferably at a flow rate of 300 to 700 μL / min, but is not limited thereto.

[0023] At this time, the pressurizing means pressurizes the fluid so that the flow direction of the fluid within the first and second channels is maintained in one direction, and can pressurize the fluid so that the fluid passing near the first chamber within the first channel flows out of the first channel, passes through the second channel, and then flows back into the first channel and passes near the second chamber.

[0024] The present invention also provides a multi-organoid testing method using a multi-organoid culture device, wherein the multi-organoid culture device further comprises a reservoir having one end fluidically connected to the first fluid path and the other end fluidly connected to the outside of the body; a culture step of culturing the first organoid and the second organoid in the first chamber and the second chamber; and a first test step of testing the cultured first organoid and the second organoid.

[0025] At this time, the culture step may include an inoculation step of inoculating a first organoid into a first chamber and inoculating a second organoid into a second chamber; and a stabilization step of stabilizing the inoculated first organoid and second organoid for a predetermined time.

[0026] At this time, the first test step may include a first solution injection step of injecting a first solution circulating in a first fluid path; and a first test evaluation step of evaluating changes in one or more of the first organoid, the second organoid, and the first fluid path.

[0027] At this time, the first test evaluation step can be repeated multiple times according to the elapsed time of a preset period.

[0028] At this time, a second test step for testing the effect of a predetermined second solution after the first test step may be further included.

[0029] At this time, the second test step may include: a second solution injection step of injecting a second solution through a reservoir to test the effect applied to the first organoid and the second organoid; and a second test evaluation step of evaluating changes in one or more of the first organoid, the second organoid, and the first flow path after the injection of the second solution.

[0030] The present invention also provides a method for manufacturing a metabolic disease model using the multi-organoid culture device.

[0031] The present invention also provides a drug screening method comprising the step of treating a model prepared by the above-described manufacturing method with a candidate substance for the prevention or treatment of metabolic diseases.

[0032]

[0033] The multi-organoid culture device according to the present invention enables efficient metabolite exchange between liver organoids and pancreatic organoids through convection-based mass transfer, and by providing separate culture environments for different organoids, it suppresses tissue-specific functional degradation that may occur due to mixed media and can stably maintain cell viability and functional characteristics during long-term culture. In addition, by exhibiting a rapid glucose homeostasis reproduction effect capable of adjusting to normal blood glucose levels similar to the in vivo environment within 2 hours after the injection of high-concentration glucose, it can precisely implement a liver-pancreatic axis disease model that reflects the pathological association between obesity-induced MASLD and T2DM. Furthermore, the device of the present invention can be utilized as a platform for evaluating the efficacy of candidate drugs related to metabolic diseases and analyzing disease mechanisms.

[0034]

[0035] FIG. 1 is a side view illustrating a multi-organoid culture device according to one embodiment of the present invention.

[0036] FIG. 2 is an exploded view of the body of a multi-organoid culture device according to one embodiment of the present invention.

[0037] FIG. 3 is a flowchart illustrating a multi-organoid test method according to one embodiment of the present invention.

[0038] FIG. 4 is a flowchart specifically illustrating the culture step of a multi-organoid test method according to one embodiment of the present invention.

[0039] FIG. 5 is a flowchart specifically illustrating the first test step of a multi-organoid test method according to one embodiment of the present invention.

[0040] FIG. 6 is a flowchart specifically illustrating the second test step of a multi-organoid test method according to one embodiment of the present invention.

[0041] FIG. 7 is a flowchart specifically illustrating the overall sequence of a multi-organoid test method according to one embodiment of the present invention.

[0042] Figure 8a is a schematic diagram showing the MASLD and T2DM models reproduced using a Multi-Organoid Device (MOD), the pathogenesis of MASLD and T2DM caused by obesity, and the interaction between the liver and pancreas axes.

[0043] Figure 8b is a design of a MOD comprising a 1.0 μm PTFE (polytetrafluoroethylene) membrane and three PDMS (polydimethylsiloxane) layers, in which a mouse pancreas organoid (m-PO) and a mouse liver organoid (m-LO) were cultured in each chamber of the upper layer.

[0044] FIG. 8c is a top view (left) and side view (right) of the MOD, in which a fluid is introduced through an inlet, passes through a connecting channel (CC) in the lower layer, and is discharged through an outlet. The device may further include an injection port for introducing a specific substance into the device. The injection port may be configured to deliver glucose, drugs, hormones, metabolites, or bioactive substances into the device (scale bar = 1 cm).

[0045] Figure 8d shows the results of confirming directional molecular transport within the MOD using a red dye (flow rate: 600 μL / min). Convective movement from the pancreatic organoid chamber (POC) to the liver organoid chamber (LOC) (top) and movement from the LOC to the POC (bottom) are shown, and selective organ-to-organ flow through the CC was visualized.

[0046] Figure 9a is a schematic diagram showing the step-by-step process of differentiating mouse tissue-derived stem cells into liver organoids and pancreas organoids.

[0047] Fig. 9b is a bright-field image confirming morphological changes due to differentiation in m-LO (scale bar = 50 μm).

[0048] Figure 9c shows immunofluorescence staining images of KRT19 (red), AFP (green), HNF4α (green), and ALB (red) in m-LO (cell nuclei stained with DAPI (blue), scale bar = 50 μm).

[0049] Figure 9d shows the results of quantitative analysis of the relative gene expression of Hnf4α (Hepatocyte nuclear factor 4 alpha), Krt18 (Keratin18), Krt19 (Keratin19), Alb, and Cyp17a1 in m-LO by qRT-PCR (n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, compared to expansion medium (EM).

[0050] Figure 9e is a bright-field image confirming morphological changes as differentiation progresses in m-PO (scale bar = 50 μm).

[0051] Figure 9f is an immunofluorescence staining image of INS (green), KRT19 (red), CHGA (green), and PDX1 (red) in m-POs (scale bar = 50 μm).

[0052] Figure 9g shows the results of quantitative analysis of the relative gene expression of Pdx1 (Pancreatic and duodenal homeobox 1), Nkx6.1 (NK6 homeobox 1), Ins2 (Insulin 2), Chga (chromogranin A), and Krt19 in m-PO by qRT-PCR.

[0053] Figure 10a is a schematic diagram of glucose transport within the device.

[0054] Figure 10b shows the results of comparing the glucose transport rate with the presence or absence of flow (600 μL / min) in the device of Figure 10a, the glucose concentration in each organoid chamber at 30 and 180 minutes (n=4), and the results of the glucose membrane permeability analysis (n=8, *** p < 0.001, compared to the static control group (No flow).

[0055] Figure 10c shows a schematic diagram of transport using FITC-dextran (4 kDa) as an insulin-sized substitute.

[0056] FIG. 10d shows the results of comparing the concentration of FITC-dextran (4 kDa) in the device of FIG. 10c after 3 hours, and the results of the membrane permeability analysis of FITC-dextran (4 kDa) (n=3, *** p < 0.001, compared to the static control group (No flow).

[0057] Figure 10e shows a schematic diagram of transport using FITC-dextran (70 kDa) as a substitute material similar in size to Fetuin A (FetA).

[0058] Figure 10f shows the results of comparing the concentrations measured in the device of Figure 10e after 24 hours, and the results of the membrane permeability analysis of FITC-dextran (70 kDa) (n=3, ** p < 0.01, *** p < 0.001, compared to the static control group (No flow).

[0059] Figure 11a shows the results of a comparison of 24-hour diffusion rates of FITC-dextran (4 and 70 kDa) through PTFE membranes with pore sizes of 0.2 μm and 1.0 μm (n=4, *** p < 0.001 (compared to 0.2 μm), ### p < 0.001 (compared to 1.0 μm)).

[0060] Figure 11b shows the results of the mass transfer efficiency evaluation between separated chambers (POC, LOC, and CC) via convective transport using a 1.0 μm PTFE membrane (n=4).

[0061] Figure 12a shows the computational simulation results for convective flow and mass transport in the MOD platform, specifically the simulation results for glucose, 4 kDa, and 70 kDa FITC-dextran concentrations within the device affected by fluid flow in the CC. The time-dependent concentration profiles of glucose and 4 kDa FITC-dextran were shown at 0 and 180 minutes under static (no flow) and flow conditions, and the time-dependent concentration profiles of 70 kDa FITC-dextran were shown at 0 and 12 hours under static and flow conditions.

[0062] Figure 12b shows the experimental results of Figure 12a, in which glucose concentrations were measured under no-flow and flow conditions from 0 to 180 minutes. All data are expressed as mean ± standard error (mean ± SEM) (n = 3).

[0063] Figure 12c shows the experimental results of Figure 12a, in which the concentration of 4 kDa FITC-dextran was measured under no-flow and flow conditions from 0 to 180 minutes. All data are expressed as mean ± standard error (mean ± SEM) (n = 3).

[0064] Figure 12d shows the experimental results of Figure 12a, in which the concentration of 70 kDa FITC-dextran was measured under no-flow and flow conditions from 0 to 180 minutes. All data are expressed as mean ± standard error (mean ± SEM) (n = 3).

[0065] Figure 13 shows the FITC-dextran diffusion kinetics in a separated device (SD) and a non-separated device (NSD), and is the result of comparing the material diffusion between chambers in the separated device and the non-separated device (n = 4).

[0066] Figure 14a shows the results of cell viability and function evaluation in a culture system with isolated media, and the results of cell viability analysis of HepG2 (Human hepatocellular carcinoma cell line G2) and MIN6 (Mouse insulinoma 6) after 48 hours of culture in a well plate using the Alamar Blue assay. * p < 0.05, *** p < 0.001),

[0067] Figure 14b shows Live / Dead staining images of HepG2 and MIN6 spheroids after 48 hours of culture in the isolation device (SD) and non-isolation device (NSD) (scale bar = 100 μm).

[0068] Figure 14c shows the results of comparing cell viability of HepG2 and MIN6 using Alamar Blue analysis (n=3-4, * p < 0.05, *** p < 0.001, relative to SD).

[0069] Figure 14d shows the results of measuring the albumin secretion of HepG2 and the insulin secretion of MIN6 by ELISA depending on whether the medium was separated (n=4, ** p < 0.01, *** p < 0.001, relative to SD).

[0070] FIG. 15a shows representative images and cross-sectional schematics of the separation device (SD) and non-separation device (NSD).

[0071] Figure 15b is a schematic diagram of the experimental process for comparing SD and NSD under flow conditions.

[0072] Figure 15c is a Live / Dead staining image of m-LO and m-PO cultured in SD and NSD for 4 days (scale bar = 100 μm).

[0073] Figure 15d shows the results of cell viability analysis of m-LO and m-PO using Alamar Blue assay (n=4, * p < 0.05, ** p < 0.01, *** p < 0.001, compared to NSD).

[0074] Figure 15e shows the results of the analysis of albumin secretion of m-LO and insulin secretion of m-PO using ELISA (n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, compared to NSD).

[0075] Figure 15f shows the results of the quantitative analysis of relative gene expression of Hnf4α and Krt19 in m-LO and Pdx1 and Nkx6.1 in m-PO using qRT-PCR (n = 3, p < 0.05, ** p < 0.01, compared to NSD).

[0076] Figure 16a shows the visualization results of lipid accumulation by Oil Red O staining in palmitic acid (PA) untreated control or treated HepG2 (scale bar = 200 μm).

[0077] Figure 16b shows the results of the quantitative analysis of lipid accumulation in Figure 16a (n=4, *** These are the results of the analysis of HepG2 petuin A secretion using ELISA (p < 0.001, compared to the control group) and ELISA (n=3, ** p < 0.01, compared to the control group).

[0078] Figure 16c shows the results of Live / Dead staining and cell viability analysis of HepG2 spheroids after 24 hours of palmitic acid (PA) treatment (n=3, ***p < 0.001, compared to the control group, scale bar = 200 μm). Cell viability was evaluated using Live / Dead analysis and Alamar Blue analysis.

[0079] Figure 17a is a schematic diagram of the experimental procedure for evaluating the pathological characteristics of MASLD and T2DM in MOD.

[0080] Figure 17b shows the results of cell viability analysis using Live / Dead staining at m-LO under Co-culture and Co-culture+PA conditions cultured in the device for 4 days (scale bar = 100 μm).

[0081] Figure 17c shows the results of evaluating the cell viability of m-LO in the device using Alamar Blue analysis (n=4, *** p < 0.001, compared to co-culture).

[0082] Fig. 17d is an Oil Red O staining image with or without PA treatment in m-LO (scale bar = 100 μm).

[0083] Figure 17e shows the results of the quantitative analysis of lipid content in Figure 17d (n=4, *** p < 0.001, compared to co-culture), and results of measuring FetA secretion of m-LO using ELISA (n=4, *** p < 0.001, compared to co-culture.

[0084] Figure 17f shows the results of evaluating the cell viability of m-PO according to PA treatment in single culture (m-PO and m-PO+PA) and co-culture (co-culture and co-culture+PA) environments using Alamar Blue analysis (n=4; *** p < 0.001, Co-culture comparison; ## p < 0.01, compared to m-PO+PA).

[0085] Figure 17g shows the results of hierarchical cluster analysis on the gene expression profiles of three experimental groups (m-PO+PA, Co-culture, and Co-culture+PA).

[0086] Figure 17h shows the results of Gene Ontology (GO) enrichment analysis for differentially expressed genes (DEGs) between the m-PO+PA group and the Co-culture+PA group.

[0087] Figure 17i shows the GSIS analysis results of m-PO (n = 4, ** p < 0.01, compared to co-culture).

[0088] Figure 17j shows the results of quantitative analysis of relative glucose levels and normalized area under the curve (AUC) analysis for 24 hours after 13 mM glucose injection (n = 4; *** p < 0.001, Co-culture comparison; ### p < 0.001, compared to Co-culture+PA).

[0089] Figure 17k shows the results of the analysis of insulin secretion of m-PO over 24 hours during the glucose tolerance test (GTT) performed under various conditions after 13 mM glucose infusion (n = 4; * p < 0.05, ** p < 0.01, *** p < 0.001, Co-culture comparison; # p < 0.05, compared to Co-culture+PA).

[0090] Figure 171 shows the results of the quantitative analysis of normalized AUC for the insulin secretion maximum (μg / L) in the initial response phase and the insulin concentration in the sustained response phase (n=4; * p < 0.05, ***p < 0.001, Co-culture comparison; # p < 0.05, compared to Co-culture+PA).

[0091] Figure 18a is a volcano plot showing significantly differentially expressed genes between the m-PO+PA group and the Co-culture+PA group.

[0092] Figure 18b shows the results of the analysis of expression levels of pancreatic β-cell markers (Pdx1, Chga, Ins1, and Ins2) and apoptosis-related gene (Casp3) through RNA sequencing analysis (n=3, * p < 0.05, ** p < 0.01, *** p < 0.001, compared to m-PO+PA).

[0093] Figure 18c shows the results of the analysis of m-PO cell viability under different conditions (Co-culture, Co-culture+FetA Ab+PA, and Co-culture+PA). Evaluation was performed using the Alamar Blue assay (n=3; ** p < 0.01, Co-culture comparison; # p < 0.05, compared to Co-culture+FetA Ab+PA).

[0094] Figure 18d shows the immunofluorescence staining images for cCasp3 (red) and INS (green) in m-PO, the quantitative analysis of DAPI+ and cCasp3+ areas per organoid, and the results of the quantitative analysis of INS+ and cCasp3+ areas per organoid (n = 3; * p < 0.05, *** p < 0.001 , compared to co-culture; # p < 0.05, ### p < 0.001, compared to Co-culture+FetA Ab+PA). Nuclei were stained with DAPI (blue) (scale bar = 200 μm).

[0095] Figure 19 shows the results of an in vitro glucose tolerance test (GTT) performed using a cell line in the multi-organoid device (MOD) of the present invention. Glucose levels were quantitatively analyzed for 24 hours after the injection of 13 mM glucose (n = 3).

[0096]

[0097] Hereinafter, embodiments of the present invention are described in detail with reference to the attached drawings so that those skilled in the art can easily implement the present invention. The present invention may be embodied in various different forms and is not limited to the embodiments described herein. In the drawings, parts unrelated to the explanation have been omitted to clearly explain the present invention, and the same reference numerals have been used for identical or similar components throughout the specification.

[0098] The words and terms used in this specification and claims are not limited to their ordinary or dictionary meanings, but should be interpreted in a meaning and concept consistent with the technical spirit of the invention in accordance with the principles by which the inventor defines terms and concepts to best describe his invention.

[0099] In the present invention, the terms “comprising” or “having” are intended to describe the existence of the features, numbers, steps, actions, components, parts, or combinations thereof described in the specification, and should be understood as not excluding in advance the existence or addition of one or more other features, numbers, steps, actions, components, parts, or combinations thereof.

[0100] Thickness or size has been exaggerated in the drawings to clearly express the characteristics of the configuration, and the thickness or size of the configuration shown in the drawings is not necessarily the same as the actual value.

[0101] In the present invention, the term "differentiation" refers to the phenomenon in which the structure or function of cells becomes specialized while cells divide and proliferate and the entire organism grows. That is, it refers to the process in which the cells, tissues, etc. of an organism change into a form and function suitable for performing the roles assigned to them. For example, differentiation can include not only the process of pluripotent stem cells changing into ectoderm, mesoderm, and endoderm cells, but also the process in which progenitor cells come to express specific differentiation traits.

[0102] In the present invention, the term "organoid" refers to a "mini-organoid" created using stem cells to perform minimal functions. It is characterized by being constructed in a three-dimensional structure, which allows for the creation of an environment similar to actual body organs even in a laboratory. In other words, an "organoid" refers to a three-dimensional in vitro organ-like model that reproduces the structure and function of an in vivo organ, consisting of a collection of cells that self-organize and differentiate into functional cells in three dimensions. The origin of the cells constituting this is not limited. The organoid may have an environment that allows the cells to interact with the surrounding environment during the growth process. Unlike 2D culture, 3D cell culture allows cells to grow in all directions in vitro. Accordingly, the 3D organoid in the present invention can almost perfectly mimic an organ interacting in vivo, serving as an excellent model for observing the development of treatments for diseases and the like.

[0103] In the following description, descriptions of some components may be omitted to clarify the features of the present invention.

[0104] Some embodiments of the present disclosure may be represented by functional block configurations and various processing steps. Some or all of these functional blocks may be implemented by various numbers of hardware and / or software configurations that execute specific functions. For example, the functional blocks of the present disclosure may be implemented by one or more microprocessors or by circuit configurations for a specific function. Additionally, for example, the functional blocks of the present disclosure may be implemented in various programming or scripting languages. The functional blocks may be implemented as algorithms executed on one or more processors. Furthermore, the present disclosure may employ prior art for electronic configuration, signal processing, and / or data processing, etc.

[0105] According to one embodiment of the present invention, liver organoids and pancreatic organoids were co-cultured in a device capable of convection-based mass transfer while separated by a semipermeable membrane, and palmitic acid was treated to the liver organoid to induce MASLD. It was then confirmed that the pathological characteristics of T2DM were reproduced by induced by fetuin A secreted from the liver causing apoptosis of β-cells and reduced insulin secretion in the pancreatic organoid. The multi-organoid culture device and the test method using it can effectively replicate the physiological interaction of the liver-pancreas axis in vitro and can be utilized in tests such as metabolic disease research and drug screening.

[0106] In addition, the multi-organoid device of the present invention is characterized by using separated media rather than common media. According to existing references (Nature Biomedical Engineering volume 6, pages 351-371, 2022), when using common media, it is difficult to maintain tissue-specific phenotypes by applying common culture conditions between tissues derived from different embryonic layers, and problems arise where already differentiated cells are dedifferentiated into immature and highly plastic phenotypes. Furthermore, it has been reported that abnormal gene expression is observed in specific tissues, leading to a decrease in the accuracy of drug toxicity assessment.

[0107] Therefore, in this invention, to maintain tissue-specificity and prevent functional degradation, each organoid is cultured in a separate medium optimized for the corresponding tissue. Furthermore, a structure was introduced that allows only the exchange of metabolites and signaling factors while restricting direct cell migration through a PTFE-based semipermeable membrane. As a result, it was confirmed that tissue-specific functions and viability can be preserved while maintaining inter-tissue interactions, and that drug responsiveness and pathophysiological reproducibility are also improved compared to existing methods.

[0108] FIG. 1 is a side view illustrating a multi-organoid culture device according to one embodiment of the present invention. FIG. 2 is an exploded view of the body of a multi-organoid culture device according to one embodiment of the present invention.

[0109] The present invention provides a multi-organoid culture device (1) comprising: a body (20) having a first chamber (11) in which a first organoid can be cultured and a second chamber (12) in which a second organoid can be cultured formed therein, and a first flow path (31) connected to one side of each of the first chamber (11) and the second chamber (12); a second flow path (44) fluidically connected to both ends of the first flow path (31); and a pressurizing means (42) for generating fluid flow within the first flow path.

[0110] At this time, the first organoid may be a liver organoid as an example, and the second organoid may be a pancreas organoid as an example. In this case, the multi-organoid culture device (1) according to one embodiment of the present invention may be a liver-pancreas-based multi-organoid culture device (1).

[0111] The liver organoid may have increased gene expression of Hnf4α, Krt18, and Krt19, and the pancreas organoid may have decreased expression of KRT19 and increased expression of PDX1, CHGA, and INS, but is not limited thereto.

[0112] However, this is exemplary, and the first organoid and the second organoid of the multi-organoid culture device (1) according to one embodiment of the present invention are not necessarily limited to liver organoids and pancreas organoids.

[0113] The first chamber (11) and the second chamber (12) may be formed by removing a portion of the interior of the body (20), but are not necessarily limited thereto.

[0114] For example, the first chamber (11) and the second chamber (12) may be formed by separate chamber members inserted into the body (20), but are not necessarily limited thereto.

[0115] At this time, the first chamber (11) and the second chamber (12) may be spaced apart by a predetermined distance. In this way, material exchange between the first chamber (11) and the second chamber (12) can preferably be performed only through the first flow path (31).

[0116] The first Euro (31) may be formed by removing a part of the interior of the body (20), similar to the first chamber (11) and the second chamber (12), but is not necessarily limited thereto.

[0117] The first chamber (11) and the second chamber (12) can be fluidly connected to each other at different locations on the first flow path (31).

[0118] Referring to FIG. 1, the first chamber (11) and the second chamber (12) can each be connected to the first flow path (31) at a predetermined distance apart on the first flow path (31).

[0119] At this time, a first filter (13) that controls material exchange between the first chamber (11) and the first flow path (31) may be disposed in the first connection part (24) where the first chamber (11) and the first flow path (31) are connected.

[0120] The first filter (13) may be a semipermeable filter that selectively passes a substance between the first chamber (11) and the first flow path (31) according to a predetermined standard.

[0121] As an example, the first filter (13) may be a semipermeable membrane having pores that restrict material movement according to size.

[0122] For example, when transferring substances between the first chamber (11) and the first flow path (31) by means of the first filter (13), only the necessary substances can be delivered without the first organoid cell passing through.

[0123] Likewise, a second filter (14) that controls material exchange between the second chamber (12) and the first flow path (31) may be disposed in the second connection part (26) where the second chamber (12) and the first flow path (31) are connected.

[0124] The second filter (14) may be a semipermeable filter that selectively passes a substance between the second chamber (12) and the first flow path (31) according to a predetermined standard.

[0125] As an example, the second filter (14) may be a semipermeable membrane having pores that restrict material movement according to size.

[0126] For example, when transferring material between the second chamber (12) and the first flow path (31) by means of the second filter (14), only the necessary material can be delivered without the second organoid cell passing through.

[0127] The first filter and the second filter may have a pore size of 0.1 to 2 μm, preferably 0.5 to 1.5 μm, but are not limited thereto.

[0128] A discharge channel (32) may be formed within the body (20) and connected to one end of the first channel (31) so that fluid passing through the first channel (31) can be discharged outside the first channel (31).

[0129] Likewise, within the body (20), an inlet channel (33) may be formed connected to the other end of the first channel (31) so that fluid passing through the first channel (31) may flow out of the first channel (31).

[0130] Meanwhile, the outflow path (32) and the inflow path (33) can be fluidly connected to a predetermined second path (44).

[0131] At this time, the second Euro (44) may be provided outside the body (20), unlike the first Euro (31). However, it is not necessarily limited to this, and the second Euro (44) may also be provided inside the body (20), like the first Euro (31).

[0132] As configured in this way, the first flow path (31), the outflow flow path (32), the second flow path (44), and the inflow flow path (33) can form a circulating fluid circuit.

[0133] Meanwhile, as illustrated in FIG. 1, a multi-organoid culture device (1) according to one embodiment of the present invention may further include a pressurizing means (42) for maintaining fluid flow in one direction within a first flow path (31).

[0134] The pressurizing means (42) may be connected to the second flow path (44) as illustrated, but is not limited thereto and is sufficient if it is connected to any one of the first flow path (31), the outflow flow path (32), and the inflow flow path (33) to maintain the fluid flow in one direction.

[0135] In this case, as an example, when the fluid flow within the first channel (31) is formed in a clockwise direction as shown in FIG. 1, the first chamber (11) may be positioned on the fluid flow direction side rather than the second chamber (12).

[0136] In this case, the material that has flowed out through the first chamber (11) to the first path (31) can flow into the second chamber (12) after passing through the outflow path (32), the second path (44), and the inflow path (33) in sequence along the direction of fluid flow.

[0137] Accordingly, it is possible to reproduce the physiological interaction in which a substance passing through the organ modeled by the first organoid is delivered to the organ modeled by the second organoid via the circulatory system.

[0138] For example, if the first organoid is a liver organoid and the second organoid is a pancreas organoid, the substance generated in the first organoid passes through the second fluid path (44) along the fluid circuit during the process of being delivered to the second organoid. Through this series of processes, the physiological interaction in which the substance generated in the liver is delivered to the pancreas via the circulatory system can be reproduced.

[0139] Meanwhile, a reservoir (34) may be formed within the body (20), with one end fluidly connected to the first Euro (31) and the other end fluidly connected to the outside of the body (20).

[0140] Accordingly, the user can inject a specific drug or solution into the fluid circuit formed by the first flow path (31) and the second flow path (44) through the reservoir (34).

[0141] At the same time, the user can also collect fluid through the reservoir (34) and analyze the components of the fluid passing through the first flow path (31).

[0142] The reservoir (34) can be connected to the first Euro (31) and a predetermined reservoir joint (35).

[0143] In the illustrated embodiment, the reservoir joint (35) is formed on the first flow path (31), but this is an exemplary location and is not necessarily limited thereto.

[0144] For example, the reservoir joint (35) may be formed at one location on the outflow path (33), the second path (44), and the inflow path (33).

[0145] Meanwhile, referring to FIG. 2, the body (20) of the multi-organoid culture device (1) according to one embodiment of the present invention may be formed with a three-stage assembly structure of an upper layer, a middle layer, and a lower layer.

[0146] More specifically, the body (20) of the multi-organoid culture device (1) according to one embodiment of the present invention may be formed by combining a first plate (20a) forming an upper layer, a second plate (20b) forming a middle layer, and a third plate (20c) forming a lower layer.

[0147] The description of the upper layer described in the present specification below may be replaced with the description of the first plate (20a), the description of the middle layer with the description of the second plate (20b), and the description of the lower layer with the description of the third plate (20c).

[0148] In addition, conversely, the description of the first plate (20a) can be replaced with a description of the upper layer, the description of the second plate (20b) with a description of the middle layer, and the description of the third plate (20c) with a description of the lower layer.

[0149] Referring to FIG. 2, a first flow path groove (21a) may be formed in the third plate (20c) in which the recessed portion extends in one direction while the upper surface is recessed.

[0150] The first Euro home (21a) can be formed into the first Euro (31) when the body (20) is fully assembled.

[0151] At this time, based on FIG. 2, an inflow channel groove (22c) that becomes part of the inflow channel (33) may be formed at the left end of the first channel groove (21a), and an outflow channel groove (23c) that becomes part of the outflow channel (32) may be formed at the right end of the first channel groove (21a).

[0152] Additionally, a reservoir groove (25c) may be formed on one side of the first Euro groove (21a), which is connected to the first Euro groove (21a) and serves as the end portion of the reservoir (34).

[0153] The second plate (20b) can be laminated on the third plate (20c).

[0154] At this time, based on Figure 2, a first connecting part (24) and a second connecting part (26) that penetrate the second plate (20b) in the height direction of the second plate (20b) may be formed on the second plate (20b).

[0155] After the body (20) is assembled, a first filter (13) and a second filter (14) may be respectively placed on the first connecting part (24) and the second connecting part (26) in the multi-organoid culture device (1) according to one embodiment of the present invention.

[0156] Additionally, based on FIG. 2, an inflow channel hole (22b) and an outflow channel hole (23b) may be formed in the second plate (20b) at positions corresponding to the inflow channel groove (22c) and the outflow channel groove (23c) of the third plate (20c), respectively.

[0157] Likewise, a reservoir hole (25b) may be formed on the second plate (20b) at a position corresponding to the reservoir groove (25c).

[0158] The first plate (20a) can be laminated on the second plate (20b).

[0159] Although not shown in FIG. 2, a first chamber (11) may be formed within the first plate (20a) at a position corresponding to the first connecting part (24), and a second chamber (12) may be formed at a position corresponding to the second connecting part (26).

[0160] Additionally, an inflow channel groove may be formed at a position corresponding to the inflow channel hole (22b) of the first plate (20a), and an outflow channel hole may be formed at a position corresponding to the outflow channel hole (23b).

[0161] Likewise, a reservoir hole may be formed at a position on the first plate (20a) corresponding to the position of the reservoir hole (25b).

[0162] The present invention also provides a multi-organoid testing method using the multi-organoid culture device, wherein the multi-organoid culture device further comprises a reservoir having one end fluidically connected to the first fluid path and the other end fluidly connected to the outside of the body; a culture step of culturing the first organoid and the second organoid in the first chamber and the second chamber; and a first test step of testing the cultured first organoid and the second organoid.

[0163] FIG. 3 is a flowchart illustrating a multi-organoid testing method according to an embodiment of the present invention. FIG. 4 is a flowchart specifically illustrating a culture step (S100) of a multi-organoid testing method according to an embodiment of the present invention. FIG. 5 is a flowchart specifically illustrating a first testing step (S200) of a multi-organoid testing method according to an embodiment of the present invention. FIG. 6 is a flowchart specifically illustrating a second testing step (S300) of a multi-organoid testing method according to an embodiment of the present invention. FIG. 7 is a flowchart specifically illustrating the overall sequence of a multi-organoid testing method according to an embodiment of the present invention.

[0164] A multi-organoid testing method according to one embodiment of the present invention is a multi-organoid testing method that utilizes a multi-organoid culture device (1) according to one embodiment of the present invention to culture multi-organoids in each chamber and performs tests related to the mechanism of invention and the development of therapeutic agents on the cultured organoids.

[0165] At this time, referring to FIG. 3 and FIG. 7, a multi-organoid test method according to one embodiment of the present invention may include a culture step (S100) of culturing a first organoid and a second organoid in a first chamber (11) and a second chamber (12), respectively; a first test step (S200) of testing changes by introducing a first solution containing a predetermined substance into the cultured first organoid and second organoid; and a second test step (S300) of testing changes by introducing a second solution such as a therapeutic agent (e.g., high concentration glucose or high concentration glucose and metformin).

[0166] Referring to FIG. 4, the culture step (S100) may include an inoculation step (S110) of inoculating a first organoid into a first chamber (11) and a second organoid into a second chamber (12), and a stabilization step (S120) of stabilizing the inoculated first organoid and second organoid for a predetermined time.

[0167] At this time, while the inoculation step (S110) and the stabilization step (S120) are performed, the first chamber (11) and the second chamber (12) can be kept isolated from each other so that material exchange between them is minimized.

[0168] Accordingly, the accuracy and reliability of the tests performed in the first test stage (S200) and the second test stage (S300) can be improved.

[0169] After the stabilization step (S120) is performed, the first test step (S200) can be performed.

[0170] Referring to FIG. 5, the first test step (S200) may include a first solution injection step (S210) for injecting a first solution circulating through the first fluid path (31), and a first test evaluation step (S220) for evaluating changes in one or more of the first organoid, the second organoid, and the first fluid path (31). At this time, the first solution may be, for example, a glucose solution or a palmitic acid solution.

[0171] The first solution may be a solution that functions similarly to blood circulating in the circulatory system, and the first solution may be injected into the first flow path (31), and a fluid flow in one direction may be generated within the first flow path (31) by a pressurizing means (42).

[0172] At this time, the first solution can circulate through the first path (31) and the second path (44).

[0173] For example, the first solution may be a glucose solution or a palmitic acid solution, and the first solution may flow within the first flow path (31) and the second flow path (44), and pass through the first filter (13) or the second filter (14) to move to the first chamber (11) or the second chamber (12).

[0174] At this time, if the first organoid is a liver organoid and the second organoid is a pancreas organoid, the first solution transferred to the first chamber (11) can be applied to the first organoid.

[0175] Accordingly, a substance such as petuin A can be released from the first organoid, and the substance released from the first organoid can pass through the first filter (13) depending on the particle size.

[0176] At this time, in the multi-organoid test method according to one embodiment of the present invention, since the fluid flows clockwise on the first flow path (31) with reference to FIG. 1, the substance released from the first organoid and passed through the first filter (13) can exit the first flow path (31), pass through the second flow path (44), and then enter the first flow path (31) again, and then pass through the second filter (14) to move to the second organoid.

[0177] Accordingly, the substance released from the first organoid is not immediately delivered to the second organoid, but can be delivered to the second organoid located in the second chamber (12) after passing through both the first flow path (31) and the second flow path (44) corresponding to the circulatory system.

[0178] Accordingly, the multi-organoid test method according to one embodiment of the present invention makes it possible to reproduce the physiological interaction between the organs simulated by the first organoid and the second organoid by applying a convection-based metabolic material delivery system.

[0179] After the first solution injection step (S210) is performed, a first test evaluation step (S220) can be performed to evaluate the change resulting from the injection of the second solution.

[0180] The first test evaluation step (S220) may be performed one or more times according to the elapsed time after the first solution is introduced.

[0181] For example, the first test evaluation step (S220) may be performed once after a set time following the injection of the first solution, and it may also be performed repeatedly according to a set time interval or a set time list.

[0182] At this time, the first test evaluation step (S220) can be performed by investigating the chemical components of one or more locations among the first chamber (11), the second chamber (12), the first organoid, the second organoid, and the first flow path (31).

[0183] In addition, the first test evaluation step (S220) can also be performed by taking a sample from the reservoir (34) and investigating the change.

[0184] After the first test evaluation step (S220) is completed, the second test step (S300) can be performed.

[0185] Referring to FIG. 6, the second test step (S300) may include a second solution injection step (S310) for injecting a second solution through a reservoir (34) to test the effect applied to the first organoid and the second organoid, and a second test evaluation step (S320) for evaluating changes resulting from the injection of the second solution after the injection of the second solution.

[0186] At this time, the second solution may be a therapeutic agent that treats the disease mechanism according to the first solution. Accordingly, performance testing of the second solution and drug development and screening may be performed based on the evaluation results of the second test evaluation step (S320), in which the second solution is administered and changes according to the second solution are evaluated.

[0187] To avoid unnecessary repetition, the description of the second test evaluation stage (S320) will be omitted to the extent of duplication and replaced with the description of the first test evaluation stage (S220).

[0188] The present invention also provides a method for manufacturing a metabolic disease model using the multi-organoid culture device.

[0189] The above metabolic disease may be one or more selected from the group consisting of metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM). In one embodiment of the present invention, it was confirmed that the device can be used to reproduce a pathological mechanism model in which obesity-induced MASLD (Metabolic dysfunction-associated steatotic liver disease) leads to the development of T2DM (type 2 diabetes mellitus).

[0190] The above metabolic disease may be induced by palmitic acid treatment, but any substance capable of inducing MASLD can be used without restriction.

[0191] The present invention also provides a drug screening method comprising the step of treating a model prepared by the above-described manufacturing method with a candidate substance for the prevention or treatment of metabolic diseases.

[0192] The above “candidate substances for treatment” may be, but are not limited to, individual nucleic acids, proteins, other extracts or natural products, or compounds that are presumed to have the potential for the prevention or treatment of metabolic diseases according to conventional selection methods or are selected randomly.

[0193] The present invention will be described in more detail below through examples. These examples are intended solely to illustrate the present invention, and it is obvious to those skilled in the art that the scope of the present invention is not to be interpreted as being limited by these examples.

[0194]

[0195] Example 1. Experimental Materials and Methods

[0196] 1-1. MOD (Multi-Organoid Device) Design

[0197] The Multi-Organoid Device (MOD) of the present invention was fabricated using PDMS by a molding method. The design consists of an upper layer (height: 6 mm, width: 30 mm, length: 45 mm), a PTFE membrane with a pore size of 1.0 μm, a middle layer (height: 1.5 mm, width: 30 mm, length: 45 mm), and a lower layer (height: 5 mm, width: 30 mm, length: 45 mm). The PDMS layer was fabricated by mixing a silicone elastomer base and a curing agent in a weight ratio of 10:1, curing at 60°C for 4 hours, and then irreversibly bonding the assembled layers by oxygen plasma treatment. Pancreatic and liver organoids were cultured in the pancreatic organoid chamber (POC) and liver organoid chamber (LOC), respectively, located in the upper PDMS layer above the PTFE membrane. The flow rate (600 μL / min) is designed to enter through the inlet, pass through the connecting channel (CC) in the lower layer, and then be discharged through the outlet.

[0198]

[0199] 1-2. Estimation of Wall Shear Stress in CC

[0200] To evaluate the mechanical microenvironment within the MOD, the wall shear stress experienced by the organoid under perfusion conditions was estimated. The shear stress was calculated using a simplified equation for flow in a rectangular channel, as previously reported. In this equation, τ represents the wall shear stress (dyne / cm²), μ is the dynamic viscosity of the aqueous medium at 37 °C (~0.01 g / cm·s), Q is the flow rate (cm³ / s), and w and h represent the channel width and height (cm), respectively:

[0201] [Equation 1]

[0202]

[0203] For MOD, Q was set to 0.01 cm³ / s (600 μL / min), and the channel size was set to a width of 0.7 cm (w) and a height of 0.3 cm (h). Substituting these values ​​into the equation, the wall shear stress within the CC was calculated to be approximately 0.0095 dyne / cm².

[0204]

[0205] 1-3. Generation of mouse tissue-derived liver and pancreas organoids

[0206] Mouse liver organoids (m-LO) and mouse pancreatic organoids (m-PO) were formed according to previously reported protocols, respectively (M. Huch et al, Long-term culture of genome-stable bipotent stem cells 717 from adult human liver, Cell, 160 (2015) 299-312). For organoid culture, 6–8-week-old male C57BL / 6 mice were sacrificed, and liver and pancreatic tissues were excised and fragmented using scissors. All mouse experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of the Yonsei University Center for Laboratory Animals (Approval No.: IACUC-A-202403-1823-02). Liver and pancreas tissue fragments were incubated at 37°C for 45 minutes with shaking in a 1:1 ratio of collagenase and Dispase II at a concentration of 0.125 mg / mL each in DMEM (Dulbecco's modified Eagle medium) high-glucose medium supplemented with 1% penicillin / streptomycin and 1% FBS (fetal bovine serum). After enzyme treatment, the supernatants of the liver and pancreas were collected in 70 μm and 40 μm filters, respectively, and the remaining tissue fragments were vigorously pipetted with organoid basal medium (Advanced DMEM / F12) supplemented with 1% penicillin-streptomycin, 1% HEPES, and 1% Glutamax to increase cell yield. The collected ductal cells, including stem cells, were centrifuged at 250 g at 4 ℃ for 5 minutes, and then resuspended in ACK (Ammonium-Chloride-Potassium) lysis buffer to remove red blood cells (RBCs).Subsequently, 40,000 centrifuged bile duct cells were inoculated into a 48-well plate encapsulated with 30 μL of growth factor reduced Matrigel. Culture medium was added to the organoid-containing hydrogel structures in each well of the 48-well plate.

[0207]

[0208] 1-4. Mouse Liver and Pancreas Organoid Culture

[0209] The mouse liver organoid isolation medium comprises a liver organoid expansion medium (m-LO expansion medium (EM)) containing Wnt3a conditioning medium (30% (v / v)), 25 ng / mL mouse noggin, and 10 μM ROCK (Rho-associated coiled-coil containing protein kinase) inhibitor. m-LO EM is a medium supplemented to the organoid base medium with 10% (v / v) R-spondin1 conditioning medium, B27, N2 supplement, 10 mM nicotinamide, 1 mM N-acetylcysteine, 50 ng / mL mouse EGF (epidermal growth factor), 100 ng / mL human FGF (fibroblast growth factor), 10 nM human gastrin I, and 50 ng / mL human HGF (hepatocyte growth factor). Mouse m-LO isolation medium was used for the initial 3 days, after which the m-LO EM was replaced every 2 days and subculture was performed every 5 to 7 days. To further differentiate m-LO, the medium was changed to liver differentiation medium (DM). Mouse liver differentiation medium consists of a base medium containing B27 supplement (with or without vitamin A), 1 mM N-acetylcysteine, 10 nM human gastrin I (human gastrin I, 50 ng / mL mouse EGF, 100 ng / mL recombinant human FGF10, 50 nM A83-01, 10 μM N-[N-(3,5-difluorophenacetyl)-l-alanyl]-s-phenylglycine t-butyl ester (DAPT), and 3 μM dexamethasone.

[0210] m-PO expanded medium (EM) consisted of a base medium containing 10% (v / v) R-spondin1 conditioned medium, vitamin A-excluding B27 (B27 minus vitamin A), 10 mM nicotinamide, 1 mM N-acetylcysteine, 50 ng / mL mouse EGF, 100 ng / mL human FGF10, 10 nM human gastrin I, and 25 ng / mL mouse Noggin. The medium was replaced every 2 days, and subculture was performed after 7 days.

[0211] To induce differentiation into pancreatic organoids after subculture in a multi-organoid device, the medium was changed to a differentiation medium. The pancreatic organoid differentiation medium consisted of 250 nM SANT-1, 0.1 μM retinoic acid, 20 ng / mL betacellulin, 1 μM XXI, 10 μM Alk5i (Alk5 inhibitor), and 1 μM T3, excluding the R-spondin1 conditioning medium from the m-PO expansion medium.

[0212]

[0213] 1-5. Cell Culture

[0214] HepG2 (human hepatocellular cell line) was cultured in DMEM medium supplemented with 10% FBS and 1% penicillin-streptomycin. Beta-TC-6 (MIN6) was cultured in DMEM supplemented with 15% FBS and 2% penicillin-streptomycin. Cells were cultured at 37°C in a humidified chamber containing 5% CO₂. In all experiments, SpheroFilm TMHepG2 and MIN6 cell spheroids produced using [method] were used, and spheroid generation followed the protocol reported in a previous study (M. Park et al, Macroencapsulation Device with Anti-inflammatory Membrane Modification Enhances Long-Term Viability and Function of Transplanted βCells, ACS 731 Applied Materials & Interfaces, (2024)).

[0215]

[0216] 1-6. Quantification of Molecular Transport and PTTE Membrane Diffusion

[0217] To evaluate convective transport and diffusion characteristics within the MOD, fluorescein isothiocyanate (FITC)-dextran molecules were used as fluorescent tracers. To simulate the movement of insulin, 4 kDa FITC-dextran (10 μg / mL), similar in size to insulin (5.8 kDa), was added to the pancreatic chamber, and aliquots were collected from the liver chamber and connecting channels. To simulate Fetuin-A (FetA, 51-67 kDa), 70 kDa FITC-dextran (10 μg / mL) was added to the liver chamber, and aliquots were subsequently collected from the pancreatic chamber and connecting channels.

[0218] In parallel with this, to evaluate the media mixing and diffusion delay, particularly through the PTFE membrane, 4 kDa and 70 kDa FITC-dextran were individually added to one chamber in each of the separated device (SD) and non-separated device (NSD). Samples were collected from adjacent chambers at regular time intervals, and fluorescence was analyzed using a plate reader (Varioskan LUX).

[0219]

[0220] 1-7. Measurement of Membrane Permeability

[0221] To evaluate glucose and size-dependent membrane permeability, glucose and FITC-dextran of different sizes (4 kDa and 70 kDa) were added to each chamber. Permeability was calculated using Equation 2 below. In Equation 2, C t ε₀ is the concentration in the pancreatic chamber or liver chamber, C0 is the initial concentration in the donor chamber, V is the volume of medium in the connected channel, A is the membrane area in contact with the cell, and Δt is the analysis time.

[0222] [Equation 2]

[0223]

[0224]

[0225] 1-8. Computer Simulation

[0226] To predict molecular transport across the membrane, computational simulations were performed using COMSOL Multiphysics. The simulations included glucose, insulin (modeled as 4 kDa FITC-dextran), and FetA (modeled as 70 kDa FITC-dextran). The flow generated by the peristaltic pump was simulated using a laminar flow interface, and the density and kinetic viscosity of the culture medium were set to 1,030 kg / m³ and 0.0025 Pa·s, respectively.

[0227] Flow through the PTFE membrane was simulated using the Darcy's Law interface, and the membrane porosity and permeability were 0.8 and 2.5 × 10⁻⁶, respectively. -14 m 2It was set to . The transport of glucose, 4 kDa FITC-dextran, and 70 kDa FITC-dextran within the MOD was simulated using the Transport of Diluted Species interface. The diffusion coefficients of glucose, 4 kDa FITC-dextran, and 70 kDa FITC-dextran in the culture medium were 9.58 × 10⁻⁶, respectively. -10 m 2 / s, 1.35×10 -10 m 2 / s, and 2.30×10 -11 m 2 Set to / s

[0228] The initial glucose concentration in the CC was set to 13 mM. The initial concentrations of 4 kDa FITC-dextran in the pancreatic chamber and 70 kDa FITC-dextran in the LOC were set to 1 μg / mL, respectively. The initial concentrations of all test substances in other regions of the MOD were set to 0 mM.

[0229]

[0230] 1-9. Co-culture of liver and pancreas organoids in MOD

[0231] To co-culture m-LO and m-PO in MOD, organoids were encapsulated in 30 μL of growth factor-reducing Matrigel and inoculated into each chamber (LOC or POC). The device was first stabilized in expansion medium for 1 day, then connected to a peristaltic pump operating at a flow rate of 600 μL / min and cultured in differentiation medium for 3 days. A DPBS (Dulbecco's Phosphate Buffered Saline) solution containing 5.5 mM glucose [with or without palmitate (PA)] was flowed through the connected channels, and the medium was replaced daily.

[0232]

[0233] 1-10. PA Treatment

[0234] A 100 mM palmitic acid (PA) stock solution was prepared by dissolving PA in 50% ethanol at 70 °C. Separately, a 10% (w / v) bovine serum albumin (BSA) solution was prepared in DPBS and maintained in a water bath at 37 °C. PA was conjugated to 1% fatty acid-free BSA and then diluted to different working concentrations (0.2, 0.25, and 0.3 mM) prior to treatment.

[0235]

[0236] 1-11. Quantitative real-time polymerase chain reaction (qRT-PCR)

[0237] Analysis was performed according to the previous protocol. In summary, total RNA was extracted from each organoid using the Qiagen RNeasy Mini Kit, and complementary DNA (cDNA) was synthesized using a cDNA synthesis kit. For qRT-PCR analysis, cDNA samples were analyzed using TaqMan ® Fast Universal PCR Master Mix or Universal SYBR ® Amplification was performed using the StepOnePlus Real-Time PCR System with Green Fast qPCR Mix. Relative gene expression levels were Comparative C T (ΔΔ T Using the ) method, it was quantified based on GAPDH (glyceraldehyde 3-phosphate dehydrogenase).

[0238] The TaqMan primers used in the present invention are as follows: Hnf4a (Mm01247712_m1), Krt19 (Mm00492980_m1), Krt18 (Mm01601704_g1), Chga (Mm00514341_m1), Pdx1 (Mm00435565_m1), Nkx6.1 (Mm00454961_m1), Ins2 (Mm00731595_gH), Gapdh (Mm99999915_g1).

[0239] In addition, the SYBR used in the present invention ® The green primers are as follows: cytochrome P450 17A1 (Cyp17a1) (F:5′-AGCTCTGTGCTGAACTGGATCC-3'(SEQ No. 1), R:5′-AGACGGTGTTCGACTGAAGCCT-3′(SEQ No. 2)), albumin (Alb) (F:5′-CAGTGTTGTGCAGAGGCTGACA-3'(SEQ No. 3), R:5′-GGAGCACTTCATTCTCTGACGG-3′(SEQ No. 4)), and Gapdh (F:5′-CTTTGTCAAGCTCATTTCCTGG-3'(SEQ No. 5), R:5′- CTTGCTCAGTGTCCTTGC-3′(SEQ No. 6)).

[0240]

[0241] 1-12. Immunocytochemical staining

[0242] Immunocytochemical staining was performed according to existing research protocols. For immunostaining, cells were separated from the growth factor-reducing Matrigel using a cell recovery solution, washed, and fixed with 4% paraformaldehyde for 30 minutes. Subsequently, the cells were permeated with 0.2% Triton X-100 for 1 hour, followed by blocking with 4% bovine serum albumin (BSA) for 4 hours.

[0243] Organoids were cultured with primary antibodies for 48 hours, and the antibodies used were as follows: rabbit anti-ALB (1:200), rabbit anti-PDX1 (1:200), mouse anti-KRT19 (1:200), mouse anti-CHGA (1:100), mouse anti-AFP (1:100), mouse anti-INS (1:100), and rabbit anti-Cleaved Caspase-3 (1:400). After washing with PBS for 24 hours, secondary antibodies were applied for an additional 24 hours: anti-mouse Alexa Fluor 488 (1:200) and anti-rabbit Alexa Fluor 594 (1:200). Cell nuclei were counterstained with DAPI.

[0244]

[0245] 1-13. Cell Viability Analysis

[0246] To evaluate cell viability, organoid culture samples were mixed with trypan blue at a 1:1 ratio to distinguish between viable and dead cells. Subsequently, 10 μL of each mixture was transferred to a Countess cell counting chamber slide, and the viable cells were counted after placing the chamber slide in an automated cell counter. In parallel, cell viability was measured using the Alamar Blue assay under 1:10 dilution conditions. After culturing cells for 4–8 hours, absorbance was measured at 570 nm using a plate reader and normalized using 600 nm as the reference wavelength. The Live / Dead analysis was performed using the Live / Dead™ Viability Kit according to the manufacturer's instructions.

[0247]

[0248] 1-14. Oil Red O Dye

[0249] Oil Red O staining was performed using the Oil Red O Staining Kit according to the manufacturer's protocol. Briefly, cells were washed with PBS, fixed with 10% formalin, and incubated for 30 minutes to 1 hour. Subsequently, they were treated with 60% isopropanol for 5 minutes and then stained with the Oil Red O working solution. Afterward, the stained lipids were extracted and quantified by measuring the absorbance at 492 nm using a plate reader.

[0250]

[0251] 1-15. Analysis and Measurement of Insulin and FetA Secretion

[0252] After collecting proteins from cells at each time point, they were analyzed using the following enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's protocol: mouse fetuin A / AHSG DuoSet, human fetuin A / AHSG DuoSet, mouse serum albumin DuoSet, human serum albumin DuoSet, and mouse insulin. FetA samples were collected from LOC, and insulin samples were collected from CC to reflect secretion and transport across the membrane.

[0253]

[0254] 1-16. FetA Antibody Neutralization Experiment

[0255] To evaluate the involvement of FetA in β-cell apoptosis, blockade experiments using mouse FetA antibodies were performed. m-LO and m-PO were co-cultured in MOD and treated for 3 days under the following conditions: (1) Control (untreated control), (2) 0.3 mM palmitate, and (3) 0.3 mM palmitate + 4 μg / mL anti-FetA antibody.

[0256]

[0257] 1-17. Analysis of GSIS (glucose-stimulated insulin secretion)

[0258] GSIS was performed according to protocols described in previous studies. MODs were prepared by incorporating m-PO and m-LO into growth factor-reducing Matrigel, respectively, and culturing them in POC and LOC. On Day 1, organoids were cultured in expansion medium, followed by culturing in differentiation medium under co-culture conditions (co-culture and co-culture+PA) for three days. Subsequently, m-PO was transferred from the device to a 48-well plate and starvated for 1 hour in 300 μL of 2.8 mM glucose solution. This was followed by stimulation in 300 μL of 20 mM glucose solution for 1 hour. This process was repeated three times. After each treatment, the solution was collected from the POC, and insulin concentrations were analyzed using a mouse insulin ELISA kit.

[0259]

[0260] 1-18. In vitro glucose tolerance test (GTT)

[0261] GTT was performed under the following experimental conditions: Co-culture, Co-culture+PA, and Co-culture+PA+Met. On day 4, a 13 mM glucose solution was injected through the injection port. Metformin was administered at a concentration of 20 μM. Solutions were collected from the connected channels at various time points; glucose concentrations were measured using the Amplex Red glucose assay, and insulin concentrations were quantified using a mouse insulin ELISA kit.

[0262]

[0263] 1-19. RNA Sequencing Analysis

[0264] For RNA sequencing, total RNA was extracted from cultured cells as described in the qRT-PCR section. RNA quality was evaluated using an Agilent 4200 TapeStation System, and RNA quantification was performed using a Qubit. For the control and experimental group RNAs, libraries were constructed using the QuantSeq 3'mRNASeq V2 Library Prep Kit FWD according to the manufacturer's instructions.

[0265] Briefly, each total RNA sample was prepared, and reverse transcription was performed after hybridizing oligo-dT primers containing Illumina-compatible sequences at the 5' end to the RNA. Subsequently, the RNA template was digested, and second-strand synthesis was initiated using random primers containing Illumina-compatible linker sequences at the 5' end. The double-strand library was purified by removing reaction components using magnetic beads. The library was then amplified to add the complete adapter sequences required for cluster generation. The final library was purified from the PCR components.

[0266] High-throughput sequencing was performed using the NextSeq 2000 platform with a single-end 100 bp read method. Raw sequencing data was preprocessed using fastp v0.23.1 to remove adapter sequences and low-quality reads. STAR v2.7.10b was used to align the filtered reads to the reference genome. Read counts were quantified using featureCounts v2.0.6. The edgeR package v3.42.4 was used for differential gene expression analysis, and TMM-normalized log2(CPM+1) transformation was applied for data normalization.

[0267]

[0268] 1-20. Statistical Analysis

[0269] All data were first tested for normality using the Shapiro-Wilk test. Since all datasets were confirmed to follow a normal distribution, parametric statistical analysis was applied according to the experimental design. One-way ANOVA was used to compare three or more groups under a single factor (e.g., different culture conditions). For experiments involving two independent variables, such as culture conditions and time, two-way ANOVA was applied. When between-group factors (e.g., culture conditions) and within-group factors (e.g., repeated measures) were present simultaneously, mixed ANOVA was applied to account for both factors of variation. For post hoc comparisons, Tukey's multiple comparison test was used for all pairwise group comparisons. Dunnett's test was applied when directly comparing multiple experimental groups with a control group.

[0270] Statistical significance criteria were defined as p < 0.05, 0.01, and 0.001, and all data were expressed as mean ± standard deviation (SD). Statistical analysis was performed using GraphPad Prism 8, and all in vitro experiments included at least three independent biological replicates.

[0271]

[0272] Example 2. Design of a Multi-Organoid Device (MOD) with a Reconstructed Liver-Pancreas Axis

[0273] The present invention aims to replicate the mechanism by which obesity alters glucose metabolism to induce MASLD and T2DM by designing a MOD enhanced by convective transport and separated organoid interstitial spaces (Fig. 8a). Obesity is associated with insulin resistance, particularly in adipose tissue, which leads to increased release of free fatty acids (FFAs) into the bloodstream. These FFAs are absorbed by the liver, causing fat accumulation, inflammation, and disruption of normal metabolic processes, ultimately influencing the development of diseases such as MASLD and T2DM. Approximately 27% of these FFAs are palmitic acid (PA); increased concentrations of PA induce MASLD and increase the expression and secretion of fetuin A (FetA) in the liver. Fetuin A binds to FFAs to form an FFA-fetuin A complex, which induces T2DM by promoting β-cell apoptosis and inhibiting insulin secretion through the TLR4 (Toll-like receptor 4) signaling pathway (Fig. 8b). In this invention, we aimed to evaluate whether characteristic changes such as increased fat accumulation, lipotoxicity, and petuin A secretion could be reproduced in MODs by treating mouse liver organoids (m-LO) with PA.

[0274] In this system, metabolic interactions between m-LO and m-PO occurred through shared CCs acting as fluidic connection channels. Although CCs do not contain endothelial cells or vascular-like structures, they enable directional molecular exchange between compartments. To replicate physiological circulatory kinetics, the device of the present invention must be able to transmit signals at a rate similar to that of the human body. The human blood flow rate is approximately 5 L / min. -1 The average blood volume is 5 L, and the circulation time is approximately 1 minute. In order to achieve the same circulation time in the present invention, a peristaltic pump was used to circulate the culture medium (600 μL) at a rate of 600 μL / min so that the entire culture medium is circulated once every minute. Despite applying a relatively high flow rate (600 μL / min), the calculated shear stress (~0.0095 dyne / cm²) at the CC wall 2 ) was at a low level. In addition, considering the presence of a 1.0 μm PTFE membrane on the upper part of the channel, the shear stress actually received by the organoid is expected to be even lower, which means that the applied flow is sufficiently gentle to maintain the structural stability of the organoid. Furthermore, to simulate the portal vein blood flow from the pancreas to the liver, the device of the present invention was configured to allow the culture medium to flow from a mouse pancreas organoid (m-PO) to a mouse liver organoid (m-LO).

[0275] As a simple and effective strategy to form separate chambers so that each organoid can use its preferred culture medium, the MOD of the present invention was fabricated using a replica molding method (F. Akther et al, Surface modification techniques for 714 endothelial cell seeding in PDMS microfluidic devices, Biosensors, 10 (2020) 182.). The device of the present invention was fabricated from polydimethylsiloxane (PDMS) and consists of an upper layer, a middle layer containing a PTFE membrane with a pore size of 1.0 μm in the center, and a lower layer (Fig. 8c). Additionally, an injection port was added to allow for the selective administration of high concentrations of glucose and / or drugs. To support isolated organoid culture, the liver and pancreas organoid chambers were physically separated to prevent direct mixing of media. Instead, molecular exchange between chambers was allowed only through CC flowing from the inlet to the outlet.

[0276] To visualize this selective transport, artificial blood (red-colored dye) was injected into each organoid chamber. When injected into the POC, the dye gradually diffused through the CC to the adjacent LOC, forming a directional concentration gradient (Fig. 8d). Conversely, when artificial blood was injected into the LOC, it circulated along the system and gradually reached the POC, confirming that directional and selective organ-to-organ interactions occurred within the device (Fig. 8d).

[0277]

[0278] Example 3. Establishment of liver and pancreas organoids derived from mouse adult stem cells

[0279] To simulate a biological environment, the present invention established liver organoids and pancreatic organoids derived from mouse liver and pancreatic stem cells, and cultured them in a differentiation medium (DM) to induce liver function and pancreatic insulin secretion to reach an appropriate state (Fig. 9a). Through differentiation, distinct morphological changes, such as thickening of the lumen, were observed in both organoids (Figs. 9b and 9e).

[0280] To evaluate differentiation, immunofluorescence staining was performed for keratin 19 (KRT19), hepatocyte nuclear factor 4 alpha (Hnf4α), albumin (ALB), and alpha-fetoprotein (AFP), and the expected staining pattern was confirmed (Fig. 9c). In addition, quantitative real-time polymerase chain reaction (qRT-PCR) confirmed that gene expression of Hnf4α, Krt18, Krt19, Alb, and Cyp17a1 increased after DM treatment (Fig. 9d).

[0281] Additionally, an additional differentiation step using mature β-cell differentiation factors was introduced to promote β-cell maturation in pancreatic organoids. Through this process, the expression of KRT19, a marker of acinar / ductal lineages, decreased, while the expression of pancreatic duodenal homeobox 1 (PDX1), panendocrine cell marker (chromogranin A, CHGA), and insulin production marker increased, confirming that the pancreatic organoids successfully transitioned to a mature state (Fig. 9f). qRT-PCR analysis also showed that after differentiation, Krt19 expression decreased, while the expression of Pdx1, NK6 homeobox 1 (Nkx6.1), CHGA, and insulin 2 (Ins2) increased (Fig. 9g). These results indicate that organoid maturation using the differentiation medium was successfully achieved, and the mature liver and pancreatic organoids were subsequently integrated into MOD.

[0282]

[0283] Example 4. Improvement of mass transfer within a device through convective transport

[0284] To overcome the limitations of simple diffusion in existing organoid devices, the movement of metabolic substrates was enhanced by utilizing convection, thereby confirming improved material transport compared to devices relying on passive diffusion. To accurately monitor the glucose homeostasis pathway in obesity, the present invention analyzed glucose, insulin, and fetuin A, which are key molecules associated with the system (Figs. 10a, 10c, and 10e).

[0285] Glucose was injected into the injection port at a concentration of 13 mM to simulate a hyperglycemic state. To verify the transport of insulin and fetuin A, substitute substances with similar molecular sizes—4 kDa FITC-dextran, similar in size to insulin (5.8 kDa), and 70 kDa FITC-dextran, similar in size to fetuin A (51-67 kDa)—were injected into the POC and LOC, respectively. Additionally, to determine the optimal PTFE membrane pore size capable of rapid mass transfer, the diffusion rate was measured using membranes with pore sizes of 0.2 μm and 1.0 μm. As a result, it was confirmed that a membrane with a pore size of 1.0 μm was suitable for rapid mass transfer (Fig. 11a). In this invention, 1.0 μm was selected as the maximum pore size capable of facilitating essential mass transfer without cell passage, thereby ensuring the stability of the system. Subsequently, it was confirmed that 4 kDa and 70 kDa FITC-dextrans were selectively delivered between the LOC and POC in a time-dependent manner through the CC and across the PTFE membrane. This long-term mass exchange was significantly increased in the presence of convective flow (Fig. 11b).

[0286] In the device of the present invention, it was first confirmed that glucose transport from the connecting channel to the tissue chamber increased in the flow group compared to the static control (no flow group) (Fig. 10a). Similarly, regarding the transport of 4 kDa FITC-dextran from the pancreatic chamber to the liver chamber, it was confirmed that the transport efficiency was improved in the flow group, as the concentration of 4 kDa FITC-dextran increased in the blood vessel and liver chambers. At 180 minutes, the static control showed a transport efficiency of 20.4 ± 3.1%, while the flow group showed 58.4 ± 7.6% (Fig. 11b).

[0287] To evaluate how effectively fetuin A secreted from the liver chamber moves to the pancreatic chamber via the connecting pathway, the concentration of 70 kDa FITC-dextran was measured in each chamber. As a result, it was confirmed that the transport efficiency of 70 kDa FITC-dextran to the blood vessels and pancreatic chamber increased in the flow group, and after 24 hours, the delivery rate was 15.9 ± 8.1% for the static control group and 70.6 ± 12.4% for the flow group (Figs. 10b, 10d, 11b).

[0288] Quantitatively, compared to the no-flow condition, convective transport was confirmed to move glucose (at the 180-minute mark), 4 kDa FITC-dextran, and 70 kDa FITC-dextran 1.9 ± 0.1, 2.1 ± 0.1, and 9.1 ± 0.3 times faster, respectively, than the static control (Figs. 10b, 10d, and 10f). Through this experiment, it was confirmed that 4 and 70 kDa FITC-dextrans were delivered between the chambers via the connecting channels (Fig. 11b), thereby demonstrating that vascular connectivity between chambers was effectively implemented. The measurement time points were set based on the molecular size-dependent transport rate through the 1.0 μm porous membrane. Since low-molecular-weight substances such as glucose and insulin exhibit rapid transport and physiological effects over long periods and reactions occur within approximately 2–3 hours, their concentrations were evaluated over a period of 3 hours. On the other hand, FetA (~70 kDa) has a relatively large molecular size and low diffusivity, and is reported to move slowly through semipermeable membranes with maximum tissue accumulation occurring at approximately 24 hours; therefore, the observation time was extended in consideration of this.

[0289] Finally, it was confirmed that the membrane permeability of glucose and FITC-dextran increased in the flow group (Figs. 10b, 10d, and 10f).

[0290] Additionally, to verify these results, COMSOL Multiphysics simulations of molecular transport kinetics were performed. The simulation results for glucose, 4 kDa FITC-dextran, and 70 kDa FITC-dextran were in good agreement with experimental transport results under flow conditions (Figs. 12a to 12d), which supported the accuracy of the model and device design.

[0291] These results demonstrate that the delivery of metabolic substrates is enhanced through convective material transport, and that the device of the present invention can accurately model physiological interactions between the two organs by effectively reproducing in vivo dynamic circulation and obesity environments within the liver-pancreas axis.

[0292]

[0293] Example 5. Cell viability and function using culture medium isolated in MOD

[0294] Organoid dysfunction in existing systems is attributed to difficulties arising from the process of co-culturing different organoids in the same medium, which leads to problems in meeting the specific requirements of each organoid. In initial experiments, it was confirmed that the survival rate decreased when human liver cancer cell line (HepG2) and mouse β-cell line (MIN6) were cultured in a 1:1 mixed medium (Fig. 12a). It was confirmed that the survival rate of HepG2 and MIN6 cells decreased significantly after 48 hours not only when cultured in their respective media but also when cultured in a medium mixed in a 1:1 ratio of the two media.

[0295] To evaluate the degree of media mixing between chambers, diffusion experiments were performed using FITC-dextran (4 kDa and 70 kDa). In the non-separating device (NSD), the media components between chambers were rapidly mixed, whereas in the separating device (SD), distinct fluorescence signals were maintained for 24 hours, indicating delayed molecular diffusion and effective compartmentalization (Fig. 13).

[0296] After verifying the effects of mixed medium conditions on cell lines, the evaluation was extended to organoid culture in MODs. Subsequently, MODs were configured as SD or NSDs to compare functions and cell viability, including albumin secretion in liver organoids (m-LO) and insulin secretion in β-cells within pancreatic organoids (m-PO) (Fig. 15a). For co-culture, m-LO and m-PO were seeded into LOC and POC, respectively, stabilized in EM for one day, and then cultured in DM under flowing conditions for three days to evaluate viability and function (Fig. 15b).

[0297] A time-course experiment was performed to evaluate cell viability and function over 4 days under both NSD and SD conditions. As a result, the SD condition maintained superior organoid viability for 4 days (Figs. 15c and 15d), and viability was maintained up to 14 days. This further supported the advantages of medium separation in long-term culture.

[0298] In terms of function, albumin and insulin secretion levels were significantly higher under SD conditions, indicating improved liver and pancreatic organoid function (Fig. 15e). These results were also confirmed in HepG2 and MIN6 cells using the same device (Figs. 14a to 14d).

[0299] In addition, qRT-PCR analysis results showed that the expression of hepatocyte (Hnf4α), cholangiocyte (Krt19), and pancreatic (Pdx1 and Nkx6.1) lineage markers was significantly reduced under NSD conditions, indicating that tissue specificity was lost under mixed medium conditions (Fig. 15f).

[0300] These results suggest that the functional decline observed under non-dissociation conditions is caused by mutual interference between organ-specific medium components. In NSD, betacellulin included in the pancreatic differentiation medium induces differentiation into β-cells instead of degrading hepatocyte function, and DAPT (N-[N-(3,5-difluorophenacetyl)-l-alanyl]-s-phenylglycine t-butyl ester) included in the liver differentiation medium inhibits Notch signaling, thereby inducing apoptosis of β-cells in m-PO.

[0301] However, the device of the present invention utilizes a PTFE membrane to delay medium mixing, thereby enabling the maintenance of organoid cell viability and function. Accordingly, the present invention confirmed that organoid function is enhanced in a separated medium environment and demonstrated that it can effectively reflect the biological environment by providing a tissue-specific microenvironment.

[0302]

[0303] Example 6. Induction of MASLD-like Conditions in MOD

[0304] First, to determine whether palmitic acid (PA) treatment induces MASLD in MODs, treatment conditions were optimized using HepG2 spheroids. Treatment with 0.3 mM PA induced MASLD-related phenotypes, including lipid accumulation, increased FetA secretion, and decreased cell viability, consistent with previous reports (Figs. 16a to 16c). Based on these results, m-LOs cultured in MODs were stabilized in EM for one day, and then cultured for three days in DM under flowing conditions, either with 0.3 mM PA or without treatment (co-culture). Subsequently, on day 4, organoid analysis was performed to evaluate lipid accumulation, FetA secretion, and viability (Fig. 17a). After PA treatment, m-LOs exhibited damage to their morphological structure and reduced viability, both suggesting lipotoxicity (Figs. 17b and 17c). Oil Red O staining results confirmed an increase in lipid accumulation in the Co-culture+PA group, and FetA secretion also increased (Figs. 17d and 17e).

[0305]

[0306] Example 7. MASLD-induced β-cell death in MOD

[0307] Next, we investigated whether MASLD-induced m-LO contributes to the pathophysiology of T2DM by inducing apoptosis in β-cells within m-PO. As a first step, cell viability was evaluated after treatment with 0.3 mM PA under the following two conditions: (1) m-PO monoculture, and (2) co-culture with m-LO. Under the m-PO monoculture condition, treatment with 0.3 mM PA did not have a significant effect on cell viability. However, under the co-culture condition with m-LO, the same treatment significantly reduced the viability of m-PO, suggesting the presence of liver-derived pro-apoptotic signaling (Fig. 17f).

[0308] To further investigate whether this apoptotic effect originates specifically from MASLD-induced m-LO, RNA sequencing was performed under the following three conditions: (1) PA-treated m-PO (m-PO+PA), (2) m-PO co-cultured with untreated m-LO (Co-culture), and (3) m-PO co-cultured with PA-treated (MASLD-induced) m-LO (Co-culture+PA). Hierarchical clustering results showed that the Co-culture+PA group exhibited an independent gene expression profile distinct from the m-PO+PA and Co-culture groups, forming a separate cluster (Fig. 17g).

[0309] To clarify the molecular-level changes induced by co-culture with MASLD m-LO, Gene Ontology (GO) enrichment analysis was performed on differentially expressed genes. The analysis revealed significant enrichment of apoptosis-related pathways in the Co-culture+PA group. In particular, the apoptosis process and its positive regulation were included in the most significantly enriched GO terms, with the latter showing a higher proportion of upregulated genes (Fig. 17h). These results suggest that co-culture with MASLD m-LO organoids induces β-cell apoptosis signals.

[0310]

[0311] Example 8. Reproduction of MASLD-induced T2DM pathophysiology and evaluation of drug efficacy

[0312] In order to confirm whether the pathophysiology of T2DM was induced in the present invention, pancreatic organoids were evaluated to show reduced insulin secretion, glucose intolerance, and hyperinsulinemia. First, to confirm the reduced insulin secretion of m-PO, glucose-stimulated insulin secretion (GSIS) analysis was performed, and it was confirmed that glucose-stimulated insulin secretion was significantly lower in the PA-treated group (Co-culture+PA) than in the control group (Co-culture) (Fig. 17i).

[0313] In addition, to evaluate glucose tolerance, a GTT was performed using MOD by injecting 13 mM glucose into the connected fluid channels to simulate postprandial blood glucose and then circulating it to the POC through the CC. As a result, in the PA-treated group (Co-culture+PA), initial blood glucose decreased slightly but did not recover to normal concentrations (7.8 mM ± 0.5 mM), whereas in the Co-culture group, blood glucose decreased to the normal range within 2 hours (Fig. 17j). However, in the general cell line experiment, unlike the organoid model, blood glucose did not decrease smoothly within 2 hours (Fig. 19), which is attributed to the low insulin sensitivity of the liver cancer cell line (HepG2).

[0314] Consequently, through GSIS and GTT analyses, it was demonstrated that the MOD of the present invention is a device capable of effectively reproducing the pathophysiology of T2DM. Furthermore, it was confirmed that rapid metabolic delivery based on convective flow contributes to the rapid restoration of blood glucose levels to the normal range, and that the organoid model is more suitable than cell lines for reproducing the liver-pancreatic axis with greater precision.

[0315]

[0316] Example 9. Evaluation of metformin as a therapeutic intervention in MOD

[0317] To determine whether the rapid decrease in glucose concentration was due to insulin secreted from β-cells within m-PO, an insulin measurement experiment was performed. Simultaneously, to evaluate the potential of this device as a drug screening platform, metformin, a widely used treatment for type 2 diabetes, was applied and its effects analyzed. Metformin inhibits gluconeogenesis in the liver and promotes intracellular glucose uptake by activating the AMP-activated protein kinase (AMPK) pathway. Additionally, it stimulates insulin secretion from β-cells by increasing the expression of aquaporin-7 in the pancreas. Since these mechanisms act in combination to reduce blood glucose levels in type 2 diabetes, metformin was selected as a suitable drug candidate for verification using this device.

[0318] To confirm the characteristic hyperinsulinemia of T2DM and to analyze the effect of metformin treatment on insulin secretion, insulin secretion from m-PO was measured during the glucose tolerance test (GTT) in the control group (Co-culture), PA treatment group (Co-culture+PA), and PA treatment + metformin treatment group (Co-culture+PA+Met). Based on the GTT results, it was first confirmed that metformin treatment had a significant effect in reducing glucose concentration within 1 hour compared to Co-culture+PA (Fig. 17k). In the initial response phase (0-4 hours) after the GTT, insulin concentrations in the control group and the PA treatment + metformin treatment group (Co-culture+PA+Met) increased rapidly, reached a maximum, and then showed a decreasing trend (Fig. 17k). On the other hand, the increase in insulin in the PA treatment group (Co-culture+PA) was relatively smaller compared to the normal group. In the later time interval (12-24 hours), the control group (Co-culture) stabilized near baseline levels (1 h: 21.1 ± 0.8 μg / L; 12 h: 22.2 ± 0.3 μg / L; 24 h: 22.6 ± 0.1 μg / L), suggesting the restoration of homeostasis. On the other hand, the PA-treated group (Co-culture+PA) showed a continuous increase in insulin secretion (1 h: 22.3 ± 0.9 μg / L; 12 h: 26.6 ± 0.4 μg / L; 24 h: 27.1 ± 0.5 μg / L), confirming sustained β-cell activation and potential hyperinsulinemia. Interestingly, the PA treatment + metformin treatment group (Co-culture+PA+Met) maintained insulin concentrations similar to the PA treatment group (Co-culture+PA), particularly during the sustained response phase (4-24 hours), which implies that metformin modulates the insulin response to some extent but does not restore it to normal levels (Figs. 17k and 17l).Metformin is known to act on various tissues, including the liver, muscle, and adipose tissue, but this device focuses on liver-pancreas interactions.

[0319] In addition, insulin secretion from β-cells within the m-PO of this device was found to follow the ideal response pattern (biphasic time course) generally observed in vivo. During the initial response phase (0-4 hours), insulin was rapidly secreted in response to glucose stimulation. Even after insulin secretion decreased, gradual and continuous insulin secretion was maintained during the sustained response phase (4-24 hours). Taken together, the key characteristics of type 2 diabetes were observed in this device, successfully reproducing a MASLD-induced type 2 diabetes model and demonstrating its potential as a drug screening platform.

[0320]

[0321] Example 10. Identification of the mechanism of FetA-mediated β-cell dysfunction in MOD

[0322] To further verify disease mechanisms within MOD and demonstrate the importance of multi-organ interactions in metabolic disease modeling, transcriptome changes were analyzed at the molecular level. Consistent with the transcriptome data, volcano plot analysis revealed significant abnormal expression of genes related to β-cell identity and apoptosis (Fig. 18a). The expression of major β-cell markers Pdx1, Chga, Ins1, and Ins2 decreased under the Co-culture+PA condition compared to the control group, while the expression of the apoptosis-related gene Casp3 increased significantly.

[0323] These transcriptome changes were further supported by the results of quantitative analysis based on Reads Per Kilobase Million (RPKM), a normalization method used in RNA sequencing (Fig. 18b). This indicates that inter-organ signaling from MASLD liver organoids contributes to β-cell death within MODs.

[0324] To further strengthen the mechanistic association between FetA and β-cell death, an antibody-neutralization experiment using a FetA-specific neutralizing antibody was also performed. In this experiment, cell viability was significantly reduced in the Co-culture+PA group, whereas this reduction was inhibited in the group treated with both PA and FetA antibody (Co-culture+FetA Ab+PA) (Fig. 18c). These results confirm that FetA secreted from MASLD-induced m-LO contributes to β-cell death.

[0325] To confirm whether the reduced viability actually reflects β-cell death, immunofluorescence staining of m-PO was performed using cleaved caspase-3 (cCasp3) and insulin (INS) antibodies and DAPI nuclear counterstaining. cCasp3 + / DAPI + and cCasp3 + / INS + Quantitative analysis of area at the organoid level revealed that apoptosis was significantly increased in the PA-treated group compared to the control group and the FetA Ab+PA-treated group. In particular, in the PA-treated group, cCasp3 + / INS + The ratio reached 68.6 ± 4.6%, indicating widespread apoptosis throughout the β-cells (Fig. 18d).

[0326] In summary, these results confirmed that FetA secreted from MASLD-induced liver organoids plays a central role in mediating β-cell death within MODs and contributes to T2DM-like pathophysiology. This supports the fact that this device is a highly disease-relevant platform and highlights the mechanistic importance of organ-liver signaling in metabolic disease modeling.

[0327]

[0328] [Explanation of the symbol]

[0329] 1: Multi-organoid culture device 11: First chamber

[0330] 12: Second chamber 13: First filter

[0331] 14: Second filter 20: Body

[0332] 20a: First plate 20b: Second plate

[0333] 20c: Third plate 21a: First Euro home

[0334] 22b: Inflow Euro Hole 22c: Inflow Euro Home

[0335] 23b: Leaked Euro Hole 23c: Leaked Euro Home

[0336] 24: First connection part 25c: Reservoir groove

[0337] 26: Second connection 31: First Euro

[0338] 32: Euro outflow 33: Euro inflow

[0339] 34: Reservoir 35: Reservoir Joint

[0340] 42: Pressurizing means 44: Second Euro

[0341]

[0342] The present invention is an invention carried out through the following tasks.

[0343] [National R&D projects that supported this invention]

[0344] [Project ID] 2710035669

[0345] [Assignment No.] 00332399

[0346] [Ministry Name] Ministry of Science and ICT

[0347] [Project Management (Specialized) Agency Name] Pan-Governmental Regenerative Medicine Technology Development Agency

[0348] [Project Name] Inter-Ministerial Regenerative Medicine Technology Development Project (R&D)

[0349] [Project Title] Development of Stem Cell-Based Pancreatic Tissue Regeneration Technology Using Advanced Bio-Convergence Technology

[0350] [Name of Project Performing Organization] Incheon National University Industry-Academic Cooperation Foundation

[0351] [Research Institute] 2025.01.01 ~ 2025.12.31

[0352]

[0353] [National R&D projects that supported this invention]

[0354] [Project ID] 2710033091

[0355] [Assignment No.] 00040240

[0356] [Ministry Name] Ministry of Science and ICT

[0357] [Project Management (Specialized) Agency Name] Pan-Governmental Regenerative Medicine Technology Development Agency

[0358] [Project Name] Inter-Ministerial Regenerative Medicine Technology Development Project (R&D)

[0359] [Project Title] Development of Skeletal Tissue Regeneration and Analysis Technology through Fabrication of Customized 3D Spheroid-Based Vascular Composite Tissues

[0360] [Name of Project Performing Organization] Hanyang University Industry-Academic Cooperation Foundation

[0361] [Research Institute] 2025.01.01 ~ 2025.12.31

[0362]

[0363] [National R&D projects that supported this invention]

[0364] [Project ID] 2710076952

[0365] [Project No.] NR071949

[0366] [Ministry Name] Ministry of Science and ICT

[0367] [Name of Project Management (Specialized) Agency] National Research Foundation of Korea

[0368] [Research Project Name] Individual Basic Research (Ministry of Science and ICT) (R&D)

[0369] [Research Project Title] Development of a Circulating Fluid-Based Capsule-Type Macro Device for Diabetes Treatment

[0370] [Name of Project Performing Organization] Incheon National University Industry-Academic Cooperation Foundation

[0371] [Research Institute] 2025.03.01 ~ 2026.02.28

[0372]

[0373] [National R&D projects that supported this invention]

[0374] [Project ID] 9991009031

[0375] [Project No.] 00432653 (RS-2024-00432653)

[0376] [Ministry Name] Multi-Ministry (Ministry of Science and ICT)

[0377] [Name of Project Management (Specialized) Agency] National Research Foundation of Korea

[0378] [Research Project Name] Development of Artificial Somatic Cell-Based Regenerative Therapy Technology Project

[0379] [Project Title] Development of Artificial Somatic Cell-Mediated Regeneration Technology for the Treatment of Metabolic Dysfunction and Fatty Acid Hepatitis Based on Liver Tissue-Specific Lipid Nanoparticles

[0380] [Name of Project Performing Organization] Yonsei University Industry-Academic Cooperation Foundation

[0381] [Research Institute] 2025.02.01 ~ 2025.12.31

[0382]

[0383] [National R&D projects that supported this invention]

[0384] [Project ID] 2710014872

[0385] [Assignment No.] 2022M3A9B6018217

[0386] [Ministry Name] Ministry of Science and ICT

[0387] [Name of Project Management (Specialized) Agency] National Research Foundation of Korea

[0388] [Research Project Name] Biomedical Technology Development - Next-Generation Applied Omics Project

[0389] [Project Title] Development of an Integrated Metatissue Chip for Establishing Models for Respiratory Infectious Diseases and Fatty Acid Hepatitis

[0390] [Name of Project Performing Organization] Yonsei University Industry-Academic Cooperation Foundation

[0391] [Research Institute] 2025.01.01 ~ 2025.12.31

Claims

1. A body having a first chamber formed therein for culturing a first organoid and a second chamber formed therein for culturing a second organoid, and comprising a first flow path connected to one side of each of the first chamber and the second chamber; A second fluid path fluidically connected to both ends of the first fluid path; and A multi-organoid culture device comprising: a pressurizing means for generating fluid flow within the first fluid path; 2. In Paragraph 1, A multi-organoid culture device, wherein a first filter is disposed in a first connection portion connecting the first chamber and the first flow path to selectively pass a substance between the first chamber and the first flow path, and a second filter is disposed in a second connection portion connecting the second chamber and the first flow path to selectively pass a substance between the second chamber and the first flow path.

3. In Paragraph 2, A multi-organoid culture device in which the first filter and the second filter have a pore size of 0.1 to 2 μm.

4. In Paragraph 1, A multi-organoid culture device in which the first chamber and the second chamber are spaced apart by a predetermined distance within the body.

5. In Paragraph 1, A multi-organoid culture device further comprising a reservoir, wherein one end is fluidically connected to the first Euro and the other end is fluidly connected to the outside of the body.

6. In Paragraph 1, The above body is formed by combining a first plate, a second plate, and a third plate that are stacked in one direction, and The first chamber and the second chamber are formed within the first plate, and The second plate has a first connecting part and a second connecting part formed therein that penetrate the second plate, and A multi-organoid culture device in which a first fluid path groove having a shape corresponding to the first fluid path is formed in the third plate.

7. In Paragraph 1, A multi-organoid culture device in which the first organoid is a liver organoid and the second organoid is a pancreas organoid.

8. In Paragraph 1, A multi-organoid culture device in which the pressurizing means operates at a flow rate of 100 to 1000 μL / min.

9. In Paragraph 1, The above pressurizing means pressurizes the fluid so that the flow direction of the fluid within the first fluid path and the second fluid path is maintained in one direction, The above pressurizing means is a multi-organoid culture device that pressurizes the fluid so that the fluid passing through the vicinity of the first chamber within the first flow path flows out of the first flow path, passes through the second flow path, and then flows back into the first flow path and passes through the vicinity of the second chamber.

10. A multi-organoid test method using a multi-organoid culture device according to any one of claims 1 to 9, wherein The multi-organoid culture device further includes a reservoir, one end of which is fluidically connected to the first fluid path and the other end of which is fluidly connected to the outside of the body. A culture step of culturing the first organoid and the second organoid in the first chamber and the second chamber; and A multi-organoid testing method comprising: a first testing step of testing the cultured first organoid and the second organoid.

11. In Paragraph 10, The above culture step is, An inoculation step of inoculating the first organoid into the first chamber and inoculating the second organoid into the second chamber; A stabilization step of stabilizing the inoculated first organoid and second organoid for 1 to 5 days; and A step of differentiating the stabilized first organoid and the second organoid for 1 to 5 days; A multi-organoid test method including 12. In Paragraph 10, The above first test step is, A first solution injection step of injecting a first solution circulating in the first fluid path; and A multi-organoid testing method comprising: a first test evaluation step for evaluating changes in any one or more of the first organoid, the second organoid, and the first flow path.

13. In Paragraph 12, The above first test evaluation step is, A multi-organoid test method performed repeatedly over a set period of time.

14. In Paragraph 10, A multi-organoid testing method further comprising: a second testing step for testing the effect of a predetermined second solution after the first testing step above.

15. In Paragraph 14, The above second test step is, A second solution injection step of injecting a second solution through the reservoir to test the effect applied to the first organoid and the second organoid; and A multi-organoid testing method comprising: a second test evaluation step for evaluating changes in one or more of the first organoid, the second organoid, and the first flow path after the injection of the second solution.

16. A method for manufacturing a metabolic disease model using a multi-organoid culture device according to any one of claims 1 to 9.

17. In Paragraph 16, A method for manufacturing a metabolic disease model, wherein the above metabolic disease is one or more selected from the group consisting of metabolic dysfunction-associated fatty liver disease (MASLD) and type 2 diabetes mellitus (T2DM).

18. A method for preparing a metabolic disease model according to claim 16, wherein the metabolic disease is induced by palmitic acid treatment.

19. A drug screening method comprising the step of treating a model prepared by a manufacturing method according to any one of claims 16 to 19 with a candidate substance for the prevention or treatment of metabolic diseases.